Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatednot_applicable

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

NCT00980031
completedphase_4

The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01151306
completedphase_3

The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease

NCT01277237
completedphase_4

The Effects of Atorvastatin Treatment in COPD Patients

NCT01748279

Clinical Trials (4)

Showing 4 of 4 trials
NCT00980031Not Applicable

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Terminated
NCT01151306Phase 4

The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01277237Phase 3

The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease

Completed
NCT01748279Phase 4

The Effects of Atorvastatin Treatment in COPD Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4